bioAffinity Technologies Announces Clinical Review for CyPath® Lung

What Happened

• On July 27, 2026, bioAffinity Technologies, Inc. filed an 8-K and issued a press release announcing the publication of a comprehensive clinical review and white paper authored by its Chief Medical Officer, Gordon H. Downie, MD, PhD. The paper presents a practical clinical framework for incorporating CyPath® Lung into pulmonary nodule evaluation and cancer surveillance. The press release is attached as Exhibit 99.1 to the filing.
• The filing also reports that as of July 24, 2026, the company had 7,783,061 shares of common stock outstanding and an aggregate market value of approximately $5.1 million based on the Nasdaq closing price that date.

Key Details

• Filing date: July 27, 2026 (Form 8-K, Item 8.01 Other Events).
• Author: Gordon H. Downie, MD, PhD (Company Chief Medical Officer).
• Shares outstanding: 7,783,061 as of July 24, 2026.
• Aggregate market value: ~ $5.1 million (based on Nasdaq closing price on July 24, 2026).
• Exhibit included: Press Release (Exhibit 99.1).

Why It Matters

• The clinical review/white paper is a product and clinical-communication milestone that outlines how CyPath® Lung could be used in pulmonary nodule evaluation and cancer surveillance, which may be relevant to clinicians, partners, and investors tracking commercial adoption and clinical validation.
• The filing does not include financial results or other material corporate transactions; it primarily provides product-related information and an updated snapshot of the company’s share count and market value.